NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$74.18

-0.40 (-0.54%)

(As of 03/22/2023 10:41 AM ET)

Add

Compare

Today's Range: $73.74
▼
$75.45
50-Day Range: $73.16
▼
$84.27
52-Week Range: $47.67
▼
$89.59

Volume: 35,021 shs
Average Volume: 199,633 shs
Market Capitalization: $1.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $119.25

Institutional Ownership

Krystal Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 60.6% Upside
$119.25 Price Target
Short Interest: Bearish
5.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.61
Based on 3 Articles This Week
Insider Trading: Selling Shares
$7.34 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.57) to ($2.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

167th out of 983 stocks

Biological Products, Except Diagnostic Industry

26th out of 163 stocks

3.5

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $119.25, Krystal Biotech has a forecasted upside of 60.6% from its current price of $74.25.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.71% of the float of Krystal Biotech has been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Krystal Biotech has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

3.7

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Krystal Biotech this week, compared to 1 article on an average week.
Search Interest
19 people have searched for KRYS on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,344,570.00 in company stock.
Percentage Held by Insiders
17.80% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.80% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow in the coming year, from ($5.57) to ($2.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -13.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -13.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

March 18, 2023 | americanbankingnews.com

Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Expands By 6.3%

March 6, 2023 | finance.yahoo.com

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

March 22, 2023 | PressReach (Ad)

This Stock Has Room To Run

Analysts believe this stock's product demand could rise quickly in the next few years.

March 6, 2023 | finance.yahoo.com

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

March 3, 2023 | benzinga.com

Krystal Biotech Stock (NASDAQ:KRYS), Guidance and Forecast

March 2, 2023 | finance.yahoo.com

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

February 28, 2023 | markets.businessinsider.com

Guggenheim Reaffirms Their Buy Rating on Krystal Biotech (KRYS)

February 28, 2023 | markets.businessinsider.com

Expert Ratings for Krystal Biotech

March 22, 2023 | PressReach (Ad)

Stocks Positioned For The Year

This breakthrough stock has bright future this decade.

February 28, 2023 | cnbc.com

Buy this little-known biotech stock set to rally nearly 60% as use of gene therapy grows, Goldman Sachs says

February 28, 2023 | markets.businessinsider.com

Krystal Biotech (KRYS) was upgraded to a Buy Rating at Goldman Sachs

February 27, 2023 | msn.com

Krystal Biotech GAAP EPS of -$1.25 misses by $0.26

February 27, 2023 | finance.yahoo.com

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

January 20, 2023 | seekingalpha.com

Krystal Biotech: Reached My Price Target, Waiting For A Drop

January 18, 2023 | finance.yahoo.com

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

January 10, 2023 | msn.com

FDA extends review of Krystal's topical gene therapy for skin disorder citing manufacturing data

January 9, 2023 | finance.yahoo.com

Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA

January 9, 2023 | markets.businessinsider.com

Krystal Biotech Announces FDA's 3-Month Extension Of BLA PDUFA Date And Regulatory Update For B-VEC

January 9, 2023 | finance.yahoo.com

Krystal Biotech’s stock is down on delayed PDUFA date

January 9, 2023 | finance.yahoo.com

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

December 16, 2022 | finance.yahoo.com

BofA Securities: The most promising biotech stocks in 2023

December 15, 2022 | finance.yahoo.com

Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine

December 14, 2022 | finance.yahoo.com

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

December 12, 2022 | finance.yahoo.com

12 Best Small-Cap Healthcare Stocks To Buy Now

December 6, 2022 | finance.yahoo.com

2 Risky Stocks That Could Soar in 2023

December 5, 2022 | finance.yahoo.com

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

December 1, 2022 | finance.yahoo.com

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings: 2/27/2023
Today: 3/22/2023
Next Earnings (Estimated): 5/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 119
Year Founded: 2017

Price Target and Rating

Average Stock Price Forecast: $119.25
High Stock Price Forecast: $133.00
Low Stock Price Forecast: $101.00
Forecasted Upside/Downside: +59.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-139,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -21.19%
Return on Assets: -19.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.30
Quick Ratio: 13.30

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.28 per share
Price / Book: 3.68

Miscellaneous

Outstanding Shares: 25,760,000
Free Float: 21,178,000
Market Cap: $1.92 billion
Optionable: Not Optionable
Beta: 0.87

Social Links

Key Executives

Krish S. Krishnan
Chairman, President & Chief Executive Officer

Suma M. Krishnan
Director, President-Research & Development

George Chen
Manager-Information Technology & CSV

Trevor Parry
Senior Director-Scientific Affairs

David Glynn
General Counsel & Head-Commercial & Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price forecast for 2023?: 4 brokerages have issued twelve-month price targets for Krystal Biotech's stock. Their KRYS share price forecasts range from $101.00 to $133.00. On average, they predict the company's share price to reach $119.25 in the next twelve months. This suggests a possible upside of 59.9% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2023?: Krystal Biotech's stock was trading at $79.22 on January 1st, 2023. Since then, KRYS shares have decreased by 5.9% and is now trading at $74.58.
View the best growth stocks for 2023 here.
Are investors shorting Krystal Biotech?: Krystal Biotech saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,190,000 shares, an increase of 6.3% from the February 13th total of 1,120,000 shares. Based on an average trading volume of 189,800 shares, the short-interest ratio is presently 6.3 days. Currently, 5.7% of the shares of the stock are sold short.
View Krystal Biotech's Short Interest.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings data on Monday, February, 27th. The company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.01.
What ETFs hold Krystal Biotech's stock?: ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO).
What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?: (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
What is Krystal Biotech's stock symbol?: Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
Who are Krystal Biotech's major shareholders?: Krystal Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.48%), Lord Abbett & CO. LLC (4.96%), Frazier Life Sciences Management L.P. (3.88%), Credit Suisse AG (2.65%), Point72 Asset Management L.P. (2.16%) and First Light Asset Management LLC (1.84%). Insiders that own company stock include Dino A Rossi, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Krystal Biotech's stock price today?: One share of KRYS stock can currently be purchased for approximately $74.58.
How much money does Krystal Biotech make?: Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $1.92 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.51) on an earnings per share basis.
How many employees does Krystal Biotech have?: The company employs 119 workers across the globe.
How can I contact Krystal Biotech?: Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Krystal Biotech - KRYS Stock Forecast, Price & News

Krystal Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Krystal Biotech (NASDAQ:KRYS) Stock

KRYS Stock News Headlines

KRYS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

KRYS Stock - Frequently Asked Questions

Overall MarketRank^™